Physician profile
Morris Jagodowicz
NPI 1184699308
$6,850.03
in general payments reported to CMS, 2019-2025
34 companies · $902 in 2025
The $902 reported for 2025 was more than what 94% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,223 · 2020: $380 · 2021: $1,984 · 2022: $790 · 2023: $979 · 2024: $592 · 2025: $902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,472.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,717.14 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $1,348.19 | 2020-2021 | |
| Indivior INC. | $954.85 | 2019-2025 | Sublocade |
| Teva Pharmaceuticals USA, INC. | $567.56 | 2019-2022 | |
| Horizon Therapeutics Plc | $383.50 | 2019-2022 | |
| Merz North America, INC. | $289.43 | 2021-2023 | Xeomin |
| Pfizer INC. | $186.68 | 2023-2024 | |
| Amgen INC. | $173.89 | 2021-2025 | Tezspire |
| Astrazeneca Pharmaceuticals LP | $148.58 | 2019-2024 | |
| Zyla Life Sciences, INC. | $144.59 | 2019 | |
| Genzyme Corporation | $102.86 | 2019-2024 | |
| Hikma Pharmaceuticals USA | $100.18 | 2021-2024 | Ryaltris, Kloxxado |
| Lilly USA, LLC | $69.62 | 2024-2025 | Zepbound, Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $68.97 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $54.41 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.85 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $49.34 | 2022 | |
| Abbott Laboratories | $47.05 | 2019 | |
| Glaxosmithkline, LLC. | $39.46 | 2023 | Nucala, Trelegy Ellipta |
| Allergan, INC. | $36.95 | 2020 | |
| Kaleo, INC. | $36.76 | 2019 | |
| Inspire Medical Systems, INC. | $35.36 | 2025 | Inspire |
| Biodelivery Sciences International, INC. | $35.27 | 2019 | |
| Lundbeck LLC | $30.66 | 2025 | Vyepti |
| Alkermes, INC. | $24.10 | 2021 | |
| Sunovion Pharmaceuticals INC. | $24.03 | 2019 | |
| Forte Bio-Pharma LLC | $19.97 | 2023 | Prolate, Nalocet |
| Vertical Pharmaceuticals, LLC | $17.80 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.43 | 2021 | |
| Pharming Healthcare, INC. | $16.64 | 2023 | Ruconest |
| Bioventus LLC | $15.22 | 2022 | |
| Braeburn INC. | $14.48 | 2024 | Brixadi |
| Novo Nordisk INC | $12.79 | 2023 | Wegovy |
| Novartis Pharmaceuticals Corporation | $12.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morris Jagodowicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.